Skip to main
AORT

Artivion (AORT) Stock Forecast & Price Target

Artivion (AORT) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Artivion is poised for significant growth through new product launches, international expansion, and its strong pipeline. The company's focus on cardiac and vascular solutions has been driving consistent revenue growth, with a strong gross margin of 90%. Despite short-term challenges, AORT's long-term outlook is positive, and the recent decline in share price presents an undervalued opportunity for investors. With a diversified revenue mix and a solid base business, AORT is well-positioned for continued success.

Bears say

Artivion is facing a negative outlook due to expected slowed revenue growth in the upcoming years stemming from weak product launches and poor international expansion. The company's reliance on the Medical Devices segment, specifically AMDS, for growth may be hindered by delays in FDA approval and limited addressable market. Additionally, Artivion faces risks such as competition from larger players, regulatory and reimbursement uncertainties, and exchange risk from international sales.

Artivion (AORT) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Artivion and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Artivion (AORT) Forecast

Analysts have given Artivion (AORT) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Artivion (AORT) has a Strong Buy consensus rating as of Aug 11, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $43.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $43.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Artivion (AORT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.